Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 4/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.40 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3386613 | 1.00 | TAAR1 (0.41) | TAAR1HTR2ACHRNB2CHRNA4SLC6A2 | |
| SCHEMBL3386535 | 1.00 | TAAR1 (0.41) | TAAR1HTR2ACHRNB2CHRNA4SLC6A2 | |
| SCHEMBL23354701 | 0.85 | CA2 (0.35) | CA2 | |
| SCHEMBL23354817 | 0.83 | CFTR (0.38) | SLC6A2SLC6A4SLC6A3CA2 | |
| SCHEMBL8405099 | 0.83 | GSR (0.44) | SLC6A2SLC6A4SLC6A3CA2AOC3 | |
| SCHEMBL14984000 | 0.83 | GSR (0.44) | SLC6A2SLC6A4SLC6A3CA2AOC3 | |
| SCHEMBL1739510 | 0.83 | GSR (0.44) | SLC6A2SLC6A4SLC6A3CA2AOC3 | |
| SCHEMBL7151617 | 0.82 | TAAR1 (0.47) | TAAR1HTR2ACHRNB2CHRNA4SLC6A2 | |
| SCHEMBL9626551 | 0.82 | TAAR1 (0.47) | TAAR1HTR2ACHRNB2CHRNA4SLC6A2 | |
| SCHEMBL7392343 | 0.82 | AOC3 (0.46) | CHRNB2CHRNA4SLC6A4NOS2CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023126006-A1 | CATIONIC LIPID CONTAINING FUNCTIONAL GROUP ON SIDE CHAIN, AND USE THEREOF | 厦门赛诺邦格生物科技股份有限公司 | 2023-07-06 | — | — | WO | disclosed |
| US-8101638-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2012-01-24 | — | — | US | disclosed |
| EP-1864995-B1 | BETA-LACTAMIC RGD CYCLOPEPTIDES CONTAINING GAMMA TURNS | UNIV PAIS VASCO (ES) | 2010-12-08 | — | — | EP | disclosed |
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | PEDREGAL-TERCERO CONCEPCION | 2009-01-22 | — | — | US | disclosed |
| US-7399774-B2 | 6-substituted nicotinamide derivatives as opioid receptor antagonists | ELI LILLY AND COMPANY (US) | 2008-07-15 | — | — | US | disclosed |
| EP-1864995-A1 | BETA-LACTAMIC RGD CYCLOPEPTIDES CONTAINING GAMMA TURNS | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2007-12-12 | — | — | EP | disclosed |
| US-6329405-B1 | AS ILEAL BILE ACID TRANSPORTER INHIBITOR, FOR THERAPY OF HYPERLIPEMIA | SANKYO COMPANY, LIMITED (JP) | 2001-12-11 | — | — | US | disclosed |
| CN-1287117-A | Cyclobutene derivatives, preparation method and therapeutic use thereof | SANKYO CO (JP) | 2001-03-14 | — | — | CN | disclosed |
| EP-1070703-A1 | Cyclobutene derivatives | Sankyo Company Limited (JP) | 2001-01-24 | — | — | EP | disclosed |
| US-5089609-A | 4-benzoyl azetidinones | SCHERING CORPORATION (US) | 1992-02-18 | — | — | US | disclosed |
| US-5008404-A | Preparation of azetidinones via novel protected intermediates | SCHERING CORPORATION (US) | 1991-04-16 | — | — | US | disclosed |
| US-4963670-A | Preparation of azetidinones via novel protected intermediates | SCHERING CORPORATION (US) | 1990-10-16 | — | — | US | disclosed |
| US-4827006-A | Preparation of azetidinones via novel protected intermediates | SCHERING CORPORATION (US) | 1989-05-02 | — | — | US | disclosed |
| US-4740595-A | Preparation of azetidinones via N-protected oxirancecarboxamide intermediates | SCHERING CORPORATION (US) | 1988-04-26 | — | — | US | disclosed |
| EP-0238252-A2 | Preparation of azetidinones and intermediates | SCHERING CORPORATION (US) | 1987-09-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023785-A1 | 6-SUBSTITUTED NICOTINAMIDE DERIVATIVES AS OPIOID RECEPTOR ANTAGONISTS | OPRM1, OPRK1, OPRD1 | TAAR1 336/4885HTR2A 753/4885CHRNB2 170/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.